Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Core Insights - Monte Rosa Therapeutics, Inc. is hosting a live conference call and webcast on December 16, 2025, to present interim clinical results from its Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 for metastatic castration-resistant prostate cancer patients [1] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases [3] - The company utilizes its QuEEN™ discovery engine, which integrates AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with high selectivity [3] - Monte Rosa has established a leading pipeline of first-in-class and only-in-class MGDs, with three programs currently in clinical trials, targeting autoimmune and inflammatory diseases, oncology, and more [3] - The company is engaged in collaborations with major pharmaceutical firms in immunology, oncology, and neurology [3]